IMAC (IMAC) Competitors $0.03 0.00 (-1.58%) As of 05/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock IMAC vs. THAR, CERO, WINT, EYEN, SNPX, ARTL, AXDX, MTNB, NBY, and CTCXShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Tharimmune (THAR), CERo Therapeutics (CERO), Windtree Therapeutics (WINT), Eyenovia (EYEN), Synaptogenix (SNPX), Artelo Biosciences (ARTL), Accelerate Diagnostics (AXDX), Matinas Biopharma (MTNB), NovaBay Pharmaceuticals (NBY), and Carmell (CTCX). These companies are all part of the "medical" sector. IMAC vs. Tharimmune CERo Therapeutics Windtree Therapeutics Eyenovia Synaptogenix Artelo Biosciences Accelerate Diagnostics Matinas Biopharma NovaBay Pharmaceuticals Carmell IMAC (NASDAQ:IMAC) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership, community ranking and media sentiment. Is IMAC or THAR more profitable? Tharimmune has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets IMAC-75.40% -52.17% -34.51% Tharimmune N/A -167.63%-130.18% Does the MarketBeat Community favor IMAC or THAR? IMAC received 69 more outperform votes than Tharimmune when rated by MarketBeat users. However, 100.00% of users gave Tharimmune an outperform vote while only 60.17% of users gave IMAC an outperform vote. CompanyUnderperformOutperformIMACOutperform Votes7160.17% Underperform Votes4739.83% TharimmuneOutperform Votes2100.00% Underperform VotesNo Votes Which has stronger earnings & valuation, IMAC or THAR? Tharimmune has lower revenue, but higher earnings than IMAC. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMAC$15.22M0.05-$10.54MN/AN/ATharimmuneN/AN/A-$9.32M-$7.88-0.17 Do analysts prefer IMAC or THAR? Tharimmune has a consensus price target of $17.00, indicating a potential upside of 1,140.88%. Given Tharimmune's stronger consensus rating and higher possible upside, analysts plainly believe Tharimmune is more favorable than IMAC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media favor IMAC or THAR? In the previous week, IMAC had 4 more articles in the media than Tharimmune. MarketBeat recorded 4 mentions for IMAC and 0 mentions for Tharimmune. Tharimmune's average media sentiment score of 0.00 beat IMAC's score of -0.26 indicating that Tharimmune is being referred to more favorably in the news media. Company Overall Sentiment IMAC Neutral Tharimmune Neutral Which has more volatility & risk, IMAC or THAR? IMAC has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Do institutionals & insiders have more ownership in IMAC or THAR? 24.3% of IMAC shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 10.0% of IMAC shares are held by company insiders. Comparatively, 10.0% of Tharimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryTharimmune beats IMAC on 10 of the 16 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAC vs. The Competition Export to ExcelMetricIMACSpecialty Outpatient Clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$824,000.00$814,500.00$5.33B$8.39BDividend YieldN/AN/A5.21%4.11%P/E RatioN/AN/A26.7119.71Price / Sales0.050.05386.13120.55Price / CashN/AN/A38.2534.62Price / Book0.050.056.774.50Net Income-$10.54M-$10.54M$3.23B$248.22M7 Day PerformanceN/AN/A1.80%0.56%1 Month PerformanceN/AN/A11.10%13.17%1 Year PerformanceN/AN/A17.11%7.30% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMACIMACN/A$0.03-1.6%N/A-99.0%$824,000.00$15.22M0.00106THARTharimmune1.5371 of 5 stars$1.56+3.3%$17.00+989.7%-77.0%$3.34MN/A-0.162Gap DownCEROCERo Therapeutics3.072 of 5 stars$0.62-4.9%$11.00+1,679.9%-99.5%$3.33MN/A0.008Earnings ReportAnalyst ForecastWINTWindtree Therapeutics2.2931 of 5 stars$0.91+6.7%$350.00+38,386.9%-99.6%$3.32MN/A-0.0630Earnings ReportGap DownEYENEyenovia0.9254 of 5 stars$1.17+8.4%$2.00+70.8%-97.6%$3.31M$57,336.00-0.0240News CoverageEarnings ReportGap DownSNPXSynaptogenix2.177 of 5 stars$2.38-1.2%$14.00+488.0%-54.2%$3.31MN/A-0.234Positive NewsEarnings ReportGap UpARTLArtelo Biosciences2.33 of 5 stars$1.00-2.0%$5.50+450.0%-36.9%$3.28MN/A-0.355Negative NewsGap UpAXDXAccelerate Diagnostics1.7325 of 5 stars$0.13-12.2%N/AN/A$3.28M$11.70M-0.05220Analyst ForecastGap DownHigh Trading VolumeMTNBMatinas BiopharmaN/A$0.63-10.5%N/AN/A$3.21M$1.10M-0.1330Gap DownNBYNovaBay Pharmaceuticals1.9366 of 5 stars$0.55-2.5%$0.85+54.5%-87.8%$3.20M$9.78M-0.0130News CoverageAnalyst ForecastCTCXCarmellN/A$0.15-1.3%N/A+35.8%$3.20M$32,839.000.0014Gap Up Related Companies and Tools Related Companies Tharimmune Competitors CERo Therapeutics Competitors Windtree Therapeutics Competitors Eyenovia Competitors Synaptogenix Competitors Artelo Biosciences Competitors Accelerate Diagnostics Competitors Matinas Biopharma Competitors NovaBay Pharmaceuticals Competitors Carmell Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAC) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMAC Stock Free IMAC Stock Alerts